A breast implant maker's stock could climb as GLP-1 market booms, TD Securities says
- Posted on September 2, 2026
- By CNBC
- 1 Views
- 1 min read
In brief
Establishment Labs is positioned for significant growth as GLP-1 drug adoption accelerates across the United States. The cosmetic surgery device manufacturer stands to benefit from increased discretionary spending among patients using weight-loss medications, while simultaneously expanding its breast implant portfolio in the competitive U.S. market. This dual-growth strategy could drive investor returns and strengthen the company's market position.
Summary auto-generated by AI from the original publisher's content. Editorial standards.
A breast implant maker's stock could climb as GLP-1 market booms, TD Securities says
Establishment Labs is poised to get a boost from widening GLP-1 use as it is set to expand its breast implant business in the U.S., per TD Securities.
